clinical trial · NCT03169972
ADYNOVATE Drug Use-Results Survey
Takeda·—·completed·n = 135
Hemophilia AADYNOVATE
brief summary
The purpose of this survey is to understand the following items in the actual clinical use of ADYNOVATE in patients: 1. Unexpected adverse drug reactions 2. Occurrence of adverse drug reactions in the actual clinical use 3. Factors that may affect safety and efficacy 4. Occurrence of Factor VIII inhibitor development in patients with coagulation factor VIII deficiency (hereinafter hemophilia A) 5. Safety and efficacy for hemophilia A patients who received routine prophylactic therapy and on-demand therapy
started
Feb 1, 2017
primary completion
Sep 15, 2023
completion
Sep 15, 2023
last updated
Feb 4, 2025
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol